DA
REGN icon

DCF Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

DCF Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,400
Closed -$1.15M – 100
2023
Q3 		$1.15M Buy
+1,400
New +$1.1M 0.63% 38
2022
Q2 		– Sell
-3,000
Closed -$2.1M – 85
2022
Q1 		$2.1M Buy
+3,000
New +$1.9M 0.92% 33

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DCF Advisers's REGN Position: Q1 2026 in Review

DCF Advisers reduced its Regeneron Pharmaceuticals (REGN) stake by 7.5% in Q1 2026, selling an estimated $574K and leaving 9,250 shares worth $7.15M. The position accounts for 1.91% of the portfolio, ranked #12.

DCF Advisers first reported a position in REGN in Q4 2019 and has held it in 26 quarters since. The position peaked at $10.9M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • DCF Advisers held 9,250 shares of Regeneron Pharmaceuticals worth $7.15M as of Q1 2026.
  • DCF Advisers sold 750 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $574K.
  • Regeneron Pharmaceuticals made up 1.91% of DCF Advisers's portfolio in Q1 2026, its #12 holding.
  • DCF Advisers first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • DCF Advisers's Regeneron Pharmaceuticals position peaked at $10.9M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.